Market Research Report
Non-Alcoholic Steatohepatitis Market by Drug Type, and Sales Channel - Global Opportunity Analysis and Industry Forecast, 2021-2025
|Published by||Allied Market Research||Product code||310284|
|Published||Content info||155 Pages
Delivery time: 2-3 business days
|Non-Alcoholic Steatohepatitis Market by Drug Type, and Sales Channel - Global Opportunity Analysis and Industry Forecast, 2021-2025|
|Published: June 1, 2018||Content info: 155 Pages||
The global non-alcoholic steatohepatitis (NASH) market generated $1,179 million in 2017, and is projected to reach $21,478 million by 2025, growing at a CAGR of 58.4% from 2021 to 2025.
Nonalcoholic steatohepatitis is a form of liver disease that develops in patients who are not alcoholic. The major feature in NASH is fat deposition in the liver, along with inflammation and damage to the liver. Most patients with NASH are not aware that they are suffering from a liver problem. However, NASH can become severe and can lead to cirrhosis, in which the liver is permanently damaged.
The nonalcoholic steatohepatitis (NASH) market is expected to show double digit growth during the forecast period owing to increase in prevalence of NASH across the world, strong presence of ideal pipeline molecules, higher number of unmet needs, and growth in awareness of NASH therapeutics in the developing region. Furthermore, rise in prevalence of diabetes & obesity and growth in demand for ideal therapeutics are expected to influence the market growth in near future. On the other side, lack of diagnostic technologies for NASH limit the growth of the market.
The global non-alcoholic steatohepatitis (NASH) market is segmented based on drug type, sales channel, and region. Based on drug type, the market is divided as vitamin E & pioglitazone, ocaliva, elafibranor, and selonsertib & cenicriviroc. According to sales channel, the market is classified into hospital pharmacy, online provider and retail pharmacy. Based on region, the market is studied across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
By Drug Type
By Sales Channel